HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BPDZ 154 activates adenosine 5'-triphosphate-sensitive potassium channels: in vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism.

Abstract
A novel ATP-sensitive potassium channel (K(ATP)) channel agonist, BPDZ 154 (6,7-dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide), was synthesized, and its effects on insulin-secreting cells were evaluated using electrophysiology, (86)Rb(+) and (45)Ca(2+) efflux, and RIA determinations of insulin secretion. BPDZ 154, an analog of diazoxide, inhibited both glucose-induced insulin secretion from isolated perifused islets and the secretion of insulin induced by glucose and tolbutamide. These effects were mediated by the activation of ATP-sensitive potassium channels because BPDZ 154 induced a concentration-dependent increase in channel activity that was inhibited by the sulfonylurea tolbutamide and the imidazoline efaroxan. In beta-cells isolated from patients with either nontypical hyperinsulinism (preserved K(ATP) channel function) or from the control areas of the pancreas of patients with focal hyperinsulinism, BPDZ 154 activated K(ATP) channels and was found to be more effective and less readily reversible than diazoxide. By contrast, it was not possible to activate K(ATP) channels by either diazoxide or BPDZ 154 in beta-cells from patients with hyperinsulinism as a consequence of defects in K(ATP) channel function. In beta-cells isolated from a patient with pancreatic insulinoma, K(ATP) channels were readily recorded and modulated by BPDZ 154. These data suggest that BPDZ 154 or BPDZ 154-like compounds may have therapeutic potential in the treatment of certain forms of hyperinsulinism.
AuthorsKaren E Cosgrove, Marie-Hélène Antoine, Anne T Lee, Philippa D Barnes, Pascale de Tullio, Peter Clayton, Rory McCloy, Pascal De Lonlay, Claire Nihoul-Fékété, Jean-Jacques Robert, Jean-Marie Saudubray, Jacques Rahier, Keith J Lindley, Khalid Hussain, Al Aynsley-Green, Bernard Pirotte, Philippe Lebrun, Mark J Dunne
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 87 Issue 11 Pg. 4860-8 (Nov 2002) ISSN: 0021-972X [Print] United States
PMID12414839 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-Antagonists
  • BPDZ 154
  • Benzofurans
  • Benzothiadiazines
  • Calcium Radioisotopes
  • Cyclic S-Oxides
  • Hypoglycemic Agents
  • Imidazoles
  • Insulin
  • Potassium Channels
  • Rubidium Radioisotopes
  • Adenosine Triphosphate
  • Tolbutamide
  • efaroxan
  • Glucose
Topics
  • Adenosine Triphosphate (pharmacology)
  • Adolescent
  • Adrenergic alpha-Antagonists (pharmacology)
  • Animals
  • Benzofurans (pharmacology)
  • Benzothiadiazines (pharmacology)
  • Calcium Radioisotopes (metabolism)
  • Cell Line
  • Child, Preschool
  • Cyclic S-Oxides (pharmacology)
  • Female
  • Glucose (pharmacology)
  • Humans
  • Hyperinsulinism (physiopathology)
  • Hypoglycemic Agents (pharmacology)
  • Imidazoles (pharmacology)
  • Infant
  • Insulin (metabolism)
  • Insulin Secretion
  • Insulinoma (physiopathology)
  • Islets of Langerhans (physiopathology)
  • Male
  • Pancreatic Neoplasms (physiopathology)
  • Potassium Channels (drug effects, physiology)
  • Rats
  • Rats, Wistar
  • Rubidium Radioisotopes (metabolism)
  • Tolbutamide (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: